Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024:285:333-367.
doi: 10.1007/164_2023_678.

Adrenoceptors in the Lower Urinary Tract

Affiliations
Review

Adrenoceptors in the Lower Urinary Tract

Martin Hennenberg et al. Handb Exp Pharmacol. 2024.

Abstract

Adrenoceptors importantly contribute to the physiological regulation of lower urinary tract (LUT) function and have become a target of several clinically successful treatments for major LUT diseases. In the bladder dome, β-adrenoceptor subtypes are found in multiple cell types and mediate relaxation of detrusor smooth muscle, perhaps partly indirectly by acting on afferent nerves and cells of the mucosa. β3-adrenoceptor agonists such as mirabegron and vibegron are used to treat overactive bladder syndrome. In the bladder trigone and urethra, α1-adrenoceptors cause contraction and thereby physiologically contribute to bladder outlet resistance. α1-adrenoceptors in the prostate also cause contraction and pathophysiologically elevate bladder outlet resistance leading to voiding dysfunction in benign prostatic hyperplasia. α1-adrenoceptor antagonist such as tamsulosin is widely used as a first-line option to treat LUT symptoms in men, but it remains unclear to which extent and how smooth muscle relaxation contributes to symptom relief.

Keywords: Prostate; Ureter; Urethra; Urinary bladder; α1-Adrenoceptor; β-Adrenoceptor.

PubMed Disclaimer

References

    1. Akiyama K et al (1999) KMD-3213, a uroselective and long-acting alpha(1a)-adrenoceptor antagonist, tested in a novel rat model. J Pharmacol Exp Ther 291(1):81–91 - PubMed
    1. Akiyama K et al (2001) Effect of KMD-3213, an alpha1A-adrenoceptor antagonist, on the prostatic urethral pressure and blood pressure in male decerebrate dogs. Int J Urol 8(4):177–183 - PubMed - DOI
    1. Alexandre EC et al (2016) Mirabegron relaxes urethral smooth muscle by a dual mechanism involving beta3 -adrenoceptor activation and alpha1 -adrenoceptor blockade. Br J Pharmacol 173(3):415–428 - PubMed - PMC - DOI
    1. Andersson K-E, Michel MC (2011) Urinary tract. In: Hofmann FB (ed) Handbook of experimental pharmacology, vol 202. Springer Verlag, Heidelberg, p 577
    1. Aro E et al (2015) Is there a peripheral site of action contributing to the voiding effects of alpha(2)-adrenoceptor agonists and antagonists? World J Urol 33(3):433–440 - PubMed - DOI

MeSH terms

Substances

LinkOut - more resources